Nuvectis Pharma (NVCT) stock falls as company posts interim data from a Phase 1b trial for its ovarian cancer drug candidate.

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

There are several stocks that passed through the screen and Nuvectis Pharma, Inc. (NVCT) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price ...

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.

Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 ...

In a recent move that signals confidence in Nuvectis Pharma, Inc. (NASDAQ:NVCT), CEO and Chairman Ron Bentsur has increased his stake in the company through the purchase of ...

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) – Stock analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Nuvectis Pharma in a report released on Tuesday, November 5th.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology.

Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...

Nuvectis Pharma, Inc. (NVCT) closed the last trading session at $8.15, gaining 34.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...